Amgen Inc. (NASDAQ:AMGN) Holdings Raised by Macquarie Group Ltd.

Macquarie Group Ltd. lifted its position in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 3.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 291,380 shares of the medical research company’s stock after acquiring an additional 10,418 shares during the period. Macquarie Group Ltd. owned about 0.05% of Amgen worth $70,441,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Tanglewood Legacy Advisors LLC acquired a new stake in Amgen during the fourth quarter worth about $26,000. Ruedi Wealth Management Inc. bought a new stake in shares of Amgen in the 4th quarter worth approximately $27,000. Strategic Investment Solutions Inc. IL acquired a new position in Amgen during the 1st quarter valued at approximately $28,000. GW&K Investment Management LLC grew its stake in Amgen by 200.0% during the 4th quarter. GW&K Investment Management LLC now owns 120 shares of the medical research company’s stock worth $32,000 after buying an additional 80 shares during the last quarter. Finally, General Partner Inc. bought a new position in Amgen during the 1st quarter worth $32,000. Institutional investors and hedge funds own 74.44% of the company’s stock.

Insider Buying and Selling at Amgen

In related news, EVP Murdo Gordon sold 9,558 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $262.43, for a total transaction of $2,508,305.94. Following the completion of the sale, the executive vice president now directly owns 44,308 shares in the company, valued at $11,627,748.44. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent research reports. Credit Suisse Group lowered their price target on shares of Amgen from $220.00 to $200.00 in a research report on Wednesday, July 12th. Truist Financial reaffirmed a “hold” rating and set a $260.00 price target on shares of Amgen in a report on Tuesday, September 5th. Jefferies Financial Group lifted their price objective on shares of Amgen from $275.00 to $310.00 and gave the company a “buy” rating in a research note on Monday, August 14th. Royal Bank of Canada increased their target price on shares of Amgen from $250.00 to $253.00 and gave the company a “sector perform” rating in a research report on Friday, August 4th. Finally, Mizuho boosted their price target on shares of Amgen from $214.00 to $223.00 and gave the stock a “neutral” rating in a research report on Monday, August 14th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from, the stock has an average rating of “Hold” and a consensus price target of $259.53.

Get Our Latest Research Report on AMGN

Amgen Trading Down 0.9 %

Shares of AMGN traded down $2.23 during midday trading on Wednesday, hitting $258.08. The stock had a trading volume of 795,898 shares, compared to its average volume of 2,430,371. The business has a 50-day simple moving average of $245.86 and a two-hundred day simple moving average of $237.17. The firm has a market cap of $138.05 billion, a P/E ratio of 17.55, a price-to-earnings-growth ratio of 3.20 and a beta of 0.61. The company has a current ratio of 2.77, a quick ratio of 2.48 and a debt-to-equity ratio of 8.76. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $296.67.

Amgen (NASDAQ:AMGNGet Free Report) last posted its quarterly earnings data on Thursday, August 3rd. The medical research company reported $5.00 EPS for the quarter, topping analysts’ consensus estimates of $4.44 by $0.56. Amgen had a net margin of 30.02% and a return on equity of 196.60%. The firm had revenue of $7 billion during the quarter, compared to analyst estimates of $6.66 billion. During the same quarter last year, the business posted $4.65 EPS. The company’s revenue was up 6.2% on a year-over-year basis. As a group, equities analysts forecast that Amgen Inc. will post 18.35 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Friday, August 18th were given a dividend of $2.13 per share. The ex-dividend date of this dividend was Thursday, August 17th. This represents a $8.52 dividend on an annualized basis and a yield of 3.30%. Amgen’s payout ratio is presently 57.45%.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Further Reading

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.